425: Semler Scientific to Merge with Strive in Stock Deal

Semler Scientific, a medical device company, has entered into a definitive merger agreement with Strive, Inc., where Semler Sci shareholders will receive 21.05 shares of Strive Class A common stock for each Semler Sci share.

Summary

• Semler Scientific, Inc. (Semler Sci) will merge with Strive, Inc. (Strive), with Semler Sci surviving as a wholly-owned subsidiary of Strive.
• Each outstanding share of Semler Sci common stock will be converted into the right to receive 21.05 shares of Strive Class A common stock.
• The transaction is intended to qualify as a tax-free reorganization under Section 368(a) of the U.S. Internal Revenue Code.
• Semler Sci equity awards (options) will convert into options to purchase Strive Class A common stock, retaining original terms, with accelerated vesting under specific conditions for non-employee directors or in case of termination without cause post-merger.
• The merger agreement was unanimously approved by the Boards of Directors of both Semler Sci and Strive.
• Semler Sci currently holds at least 5,021 Bitcoin, which will be transferred to Strive.
• The merger is subject to customary closing conditions, including shareholder approvals from both companies and regulatory clearances.
• Semler Sci may be required to pay a $49 million termination fee to Strive under certain circumstances, payable in cash or Bitcoin.

Sentiment

Score: 7

Explanation: The sentiment is moderately positive due to the unanimous board approvals, the strategic nature of the merger, and the intention for a tax-free reorganization. However, the presence of a significant termination fee and the inherent risks associated with any merger, particularly one involving a shift towards a digital asset-focused parent company, temper the overall positivity. The lack of immediate financial performance details for the combined entity also contributes to a cautious optimism rather than strong enthusiasm.

Positives

• Semler Sci shareholders will receive shares in Strive, potentially offering exposure to a company with a digital asset strategy.
• The transaction is intended to be a tax-free reorganization for U.S. federal income tax purposes.
• Eric Semler, a Semler Sci director, will join Strive's Board, providing some continuity and representation.
• Employee benefits for 'Affected Employees' are largely maintained for 12 months post-closing, with service credit recognition and 401(k) rollover options.

Negatives

• Semler Sci will cease to exist as an independent publicly traded entity, potentially altering its strategic focus.
• Semler Sci shareholders will own shares in Strive, a different company, which may have a different risk profile and business focus (implied by Strive's Bitcoin holdings and Semler's recent Bitcoin strategy).
• A $49 million termination fee is payable by Semler Sci under certain conditions, which could be a significant financial burden if the merger fails.
• Strive is not required to divest assets or take other actions that would impose a 'Burdensome Condition' to secure regulatory approval, potentially limiting its efforts to close the deal if significant antitrust issues arise.

Risks

• Failure to obtain necessary shareholder approvals from either Semler Sci or Strive.
• Failure to obtain regulatory approvals, including HSR Act clearance, or the imposition of a 'Burdensome Condition' by regulators.
• The occurrence of a 'Company Material Adverse Effect' or 'Parent Material Adverse Effect' prior to closing.
• The possibility that the anticipated strategic and financial benefits of the proposed transaction are not realized.
• Integration of the two companies may be more difficult, time-consuming, or costly than expected.
• Diversion of management's attention from ongoing business operations.
• Dilution caused by Strive's issuance of additional shares of its Class A common stock.
• Potential adverse reactions from customers or changes to business or employee relationships.
• Changes in Strive's or Semler Sci's share price before closing.
• Risks associated with Bitcoin and other digital assets, and the implementation of Bitcoin treasury strategies.
• General economic and market conditions, interest and exchange rates, monetary policy, laws, and regulations.

Future Outlook

The companies anticipate the merger will result in strategic and financial benefits for the combined entity, including potential cost savings and strategic gains. The transaction is expected to close by March 22, 2026, subject to shareholder and regulatory approvals. Strive intends to continue its plan to issue senior cumulative variable rate perpetual preferred equity instruments or raise additional capital.

Management Comments

• The Board of Directors of the Company has unanimously determined that this Agreement and the transactions contemplated hereby (including the Merger) are advisable, fair to and in the best interests of the Company’s stockholders.
• The Board of Directors of Parent has unanimously determined that this Agreement and the transactions contemplated hereby (including the Parent Share Issuance) are advisable, fair to and in the best interests of Parent and its stockholders.

Industry Context

This merger represents a significant strategic shift for Semler Scientific, a medical device company known for its QuantaFlo product, by integrating it into Strive, a company with substantial Bitcoin holdings and a focus on digital assets. This move could be interpreted as Semler Scientific leveraging its recent adoption of Bitcoin as a treasury asset to align with a company more deeply embedded in the digital asset space, potentially seeking to diversify its business model or capitalize on the growing interest in cryptocurrency-backed corporate strategies. It reflects a trend where companies with traditional business models explore or integrate digital asset strategies.

Comparison to Industry Standards

• The filing does not provide specific comparable companies, projects, or results to assess the merger against global benchmarks. The valuation and strategic rationale are presented internally without external industry comparisons within the document.

Management Changes

Corporate Governance

Legal Proceedings

• No litigation or similar legal action by any governmental authority seeking to prohibit or restrain the Merger is pending (a closing condition).
• No Order outstanding or threatened against or affecting the Company or its Subsidiaries that would prevent, enjoin, alter or materially delay any of the Transactions.
• No Proceeding pending or threatened against the Company or its Subsidiaries that would reasonably be expected to have a Company Material Adverse Effect.
• No Proceeding pending or threatened against Parent or its Subsidiaries that would reasonably be expected to have a Parent Material Adverse Effect.

Related Party Transactions

• The filing defines 'Related Party Contract' but does not disclose any specific related party dealings in the context of the merger itself, beyond the general definition.

Stakeholder Impact

• Shareholders (Semler Sci): Will exchange their shares for Strive Class A Common Stock, becoming shareholders of Strive.
• Shareholders (Strive): Will experience dilution due to the issuance of new shares for the merger.
• Employees (Semler Sci): 'Affected Employees' will receive comparable compensation and benefits for 12 months post-closing, with service credit recognition and 401(k) rollover options.
• Management (Semler Sci): Eric Semler, a director, will join Strive's board. Other management roles are not explicitly detailed but Semler Sci will become a subsidiary.

Next Steps

• Semler Scientific and Strive to jointly prepare and file a Registration Statement on Form S-4 (including Information Statement/Proxy Statement/Prospectus) with the SEC.
• Semler Scientific to convene a stockholder meeting to obtain the Company Stockholder Approval.
• Parent to obtain Parent Stockholder Approval for the share issuance.
• Parent to form a new Delaware corporation (Merger Sub) and cause it to execute a joinder to the agreement.
• Parent to form a Delaware limited liability company (Second Merger Sub) for the Second Merger.
• Obtain early termination or expiration of waiting periods under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 (HSR Act).
• Strive Class A Common Stock to be approved for listing on Nasdaq.
• The merger is expected to close by March 22, 2026.

Key Dates

Recommendation

The merger announcement presents a significant strategic shift for Semler Scientific, moving it under the umbrella of Strive, a company with a notable Bitcoin treasury strategy. While the unanimous board approvals and the intention for a tax-free reorganization are positive, the immediate financial implications for Semler Scientific shareholders are tied to the future performance of Strive's Class A common stock. The exchange ratio is fixed, but the value of Strive's stock, and by extension the value received by Semler Sci shareholders, will fluctuate. The integration risks, potential for regulatory hurdles (even if Strive is not obligated to accept 'Burdensome Conditions'), and the $49 million termination fee introduce elements of uncertainty. Given these factors, a 'hold' recommendation is appropriate for existing Semler Scientific shareholders to await further details on Strive's strategy, the integration process, and the market's reaction to the combined entity, rather than an immediate buy or sell based solely on this announcement. New investors should conduct thorough due diligence on Strive's business model and digital asset strategy.

Keywords

Merger Agreement, Semler Scientific, Strive Inc, Stock-for-Stock Merger, SEC Filing, Corporate Reorganization, Bitcoin Holdings, SMLR, Nasdaq, Financial Reporting